For UK patients who have been prescribed cemiplimab only

Sanofi logo

This site is under maintenance but will be live again soon

This website uses cookies to improve user experience. By clicking "Accept All", you agree to the storing of cookies on your device to enhance site navigation, measure site performance and show you personalized advertising. You can manage individual cookies preferences or withdraw your consent at any moment by clicking on the link "Cookies Settings".

For more information on how we use cookies, including the total lifespan of cookies and the identity of third-party intervening on our website, please consult the Cookies Policy, available in the site footer.

Cookie Settings

Report an Adverse Event

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme www.mhra.gov.uk/yellowcard. By reporting side effects, you can help provide more information on the safety of this medicine.

Black Triangle

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.

Us and You logo
Return to the Cemiplimab Home Page
MAT-GB-2100479 (v2.0) Date of Preparation - December 2022